“Gain of Function” Research Is Misunderstood – And That Is A Problem

Few phrases in science can empty a room of nuance faster than gain-of-function research. The moment those words appear, the public conversation often swerves into one of two ditches. In one ditch, every experiment sounds like a supervillain origin story. In the other, every concern is dismissed as panic from people who do not know a pipette from a paperclip. Neither ditch is helpful, and both are crowded.

That is a problem because the phrase gain of function is much broader than most headlines suggest. In biology, organisms gain functions naturally all the time through evolution, and researchers also use gain- and loss-of-function approaches to understand how genes, proteins, and pathogens behave. But a much smaller, more controversial subset of pathogen research can raise serious biosafety and biosecurity questions. When the entire debate gets flattened into one scary label, the public misunderstands the science, lawmakers struggle to target policy well, and trust in legitimate research takes a hit.

In plain English, this is not just a debate about whether risky pathogen research should exist. It is also a debate about definitions, oversight, communication, and whether society can discuss scientific risk without either hyperventilating or shrugging. That may not be as cinematic as “scientists create monster virus,” but it is far more useful.

What Gain-of-Function Research Actually Means

At its core, gain-of-function research means altering an organism so it does something new or does something differently than before. That can involve changing a gene, modifying expression, testing how a mutation affects behavior, or studying how microbes adapt. In many fields of biology, this is routine. It is a basic way to learn what a gene does, why a protein matters, or how a virus interacts with host cells.

That broad definition is exactly why the term causes so much confusion. To many scientists, GOF research is a wide umbrella. To many people outside science, it has become shorthand for a much narrower idea: deliberately making a pathogen more dangerous. Those are not the same thing. Conflating them is like hearing the word “vehicle” and assuming every conversation is about drag racing through a shopping mall.

Even within infectious disease research, not all gain-of-function work is equally risky. Scientists may use it to understand host range, immune escape, transmission, or drug resistance. Some experiments are low risk and tightly contained. Others may warrant heightened review, stricter controls, or rejection altogether. The point is that the phrase alone does not tell you enough. You need context: which pathogen, what change, what purpose, what safeguards, and what alternatives were considered?

The Small Subset That Drives the Big Fear

The most controversial area involves work on pathogens with pandemic potential. Over time, U.S. oversight has used narrower labels for this small slice of research, including gain-of-function research of concern, enhanced potential pandemic pathogens, and more recently the language of pathogens with enhanced pandemic potential within broader oversight policy. These labels exist for a reason: they are attempts to separate ordinary biological research from experiments that could plausibly create outsized public risk.

That distinction matters. If the public hears “gain of function” and pictures only the riskiest pathogen experiments, then thousands of ordinary studies get rhetorically thrown into the same basket. If scientists hear criticism of risky research and assume the public is attacking all modern biology, they also miss the point. Everybody loses, and the terminology does most of the damage.

Why Scientists Defend Some of This Work

Scientists do not defend controversial pathogen research because they enjoy making life difficult for public relations teams. They defend some of it because, under the right circumstances, it can answer questions that matter for pandemic preparedness, surveillance, vaccines, and treatment. Understanding which mutations affect host range, immune evasion, or drug resistance can help researchers identify threats sooner and respond more intelligently.

Historically, advocates have argued that these approaches can improve animal models, support vaccine development, and reveal how pathogens might change under real-world pressure. In virology, that knowledge can sharpen surveillance by helping experts distinguish which naturally occurring variants deserve more attention. It can also support basic science, which is the unglamorous but necessary business of figuring out how nature works before nature decides to quiz us in public.

That does not mean every claimed benefit is automatic, immediate, or impossible to obtain another way. Some critics reasonably argue that the promised payoff is sometimes speculative, delayed, or achievable through safer alternatives such as surveillance, computational modeling, pseudovirus systems, structural biology, or non-enhancing experimental designs. Fair enough. But the existence of alternatives does not automatically make all gain-of-function approaches useless. It means proposals should be judged case by case, not via slogan warfare.

Examples That Shaped the Debate

The modern public fight over this issue was heavily shaped by controversial influenza studies, especially work involving H5N1 in ferret models. Those experiments raised the obvious question: if a study can generate knowledge about transmission, can it also create unacceptable risk? That question led to intense debate over publication, oversight, and whether the scientific benefits justified the potential danger.

Then came COVID-19, and suddenly every previously nerdy biosafety argument was shoved into the middle of mainstream politics. Research involving bat coronaviruses, federal funding, and institutional oversight became part of a far larger argument about pandemic origins, public trust, and government competence. Once that happened, “gain of function” stopped being merely a technical term. It became a political symbol, and political symbols are terrible at nuance.

What Critics Are Right To Worry About

Critics are not wrong to worry. Research on dangerous pathogens can pose real risks even in trained, regulated environments. The concerns generally fall into three buckets: accidental release, deliberate misuse, and information hazards. A lab accident can happen without malicious intent. A bad actor could misuse knowledge or tools. And publishing certain methods or results can create downstream security concerns even when the research itself was legal and well supervised.

This is why biosafety and biosecurity are not optional accessories that get bolted onto a project five minutes before a committee meeting. They are the project. In the U.S., biosafety guidance emphasizes risk assessment, containment, training, and laboratory practices matched to the organism and the work being performed. Biosafety levels are not decorations on the door; they are part of the risk-management logic that determines what kinds of work can be done and how.

Critics also point out that institutions and governments do not always communicate clearly about how proposals are reviewed, why particular studies are approved, or what safeguards are in place. That lack of clarity can make even legitimate work look suspicious. In a high-trust environment, complexity is tolerable. In a low-trust environment, complexity looks like a cover story. That is not always fair, but it is politically real.

The Oversight Problem: Necessary, Messy, and Always a Little Behind

U.S. policy on risky pathogen research has evolved over time because the science keeps moving and the old categories keep proving too blunt. Oversight frameworks such as P3CO were designed to review a limited set of proposed research involving enhanced potential pandemic pathogens. Later changes broadened the discussion into more integrated oversight for dual-use research of concern and pathogens with enhanced pandemic potential. More recently, federal policy shifted again, showing that Washington can, in fact, do molecular biology’s favorite trick: mutate under pressure.

That constant policy motion reflects a real dilemma. If oversight is too narrow, risky work may slip through. If it is too broad, it can sweep up valuable low-risk research, slow preparedness, and create confusion at the institutional level. Researchers, funders, biosafety officers, and reviewers are all trying to draw lines that are scientifically meaningful, administratively workable, and publicly defensible. That is a lot to ask from a few acronyms and a stack of guidance documents.

The misunderstanding of gain-of-function research makes this harder. Public debate often treats oversight as proof that all such work is reckless, while some defenders talk as if criticism itself is the real threat. In reality, strong oversight is evidence that the system recognizes risk and is trying to manage it. The better question is not whether oversight exists, but whether it is transparent, consistent, evidence-based, and capable of adapting without turning into bureaucratic fog.

Why Misunderstanding Becomes a Public Problem

When the term is misunderstood, three bad things happen.

1. Bad language produces bad policy

If lawmakers and the public treat all gain-of-function research as identical, policy responses become blunt instruments. Bans may be too vague, exceptions too political, and reviews too inconsistent. Good governance depends on precise categories. “Anything that sounds scary” is not a category. It is a mood.

2. Trust erodes on both sides

The public starts to suspect that scientists use jargon to hide risk. Scientists start to suspect that the public only wants neat villains and simpler headlines. The result is a trust deficit in which every clarification sounds evasive and every criticism sounds uninformed. That is a miserable foundation for policy in an area that depends on both expertise and democratic legitimacy.

3. Preparedness can suffer

If the debate becomes too distorted, research institutions may avoid valuable work not because it is unsafe, but because the reputational and political cost becomes unpredictable. At the same time, dangerous work may not actually be governed better; it may just be governed more noisily. That is the worst of both worlds: less clarity, less trust, and no guarantee of more safety.

How We Should Talk About It Instead

A smarter public conversation would start with a few simple rules.

First, stop using “gain of function” as if it describes one thing. It does not. Ask what function, in what organism, under what conditions, and with what oversight.

Second, distinguish broad biological methods from the narrower category of research that may enhance pandemic risk. Most gain-of-function work is not the stuff of congressional theater.

Third, demand plain-English explanations from scientists and institutions. If a project is worth doing, its defenders should be able to explain why, what the safeguards are, and why safer alternatives are insufficient.

Fourth, accept that critics may be raising legitimate concerns without being anti-science. Conversely, accept that defending some controversial research does not make a scientist reckless or deceptive by default.

Fifth, focus on governance quality. The public should care about risk assessment, containment, training, transparency, reporting, and review standards more than catchphrases. Drama is easy. Oversight is harder. Oversight is also the part that matters.

Experiences From the Real World of Misunderstanding

The human side of this issue rarely gets enough attention, so it is worth slowing down here. Consider the experience of a university biosafety officer who is not trying to win an ideological war, but simply trying to decide whether a proposal belongs in ordinary review or enhanced review. If the language in public debate is sloppy, that person is stuck translating between scientific detail, institutional liability, and public fear. One group says, “This is basic virology.” Another says, “This is dangerous gain-of-function.” The biosafety officer is left muttering, “Could everyone please define their nouns?”

Now think about the experience of a virologist whose work has nothing to do with creating unusually risky pathogens but who uses gain-of-function methods in the broad biological sense. Suddenly, a technical phrase that once belonged mostly in journal articles now lands like a grenade in public discussion. The researcher may find their work lumped together with the most controversial experiments on the planet, even when the actual project is narrow, contained, and routine. That does not just create frustration. It can distort hiring, funding, collaboration, and how institutions talk about their own science.

Then there is the experience of the ordinary reader. Most people do not have time to read federal guidance, committee reports, biosafety manuals, and workshop summaries for fun. They meet this topic through headlines, clips, arguments, and political sound bites. If one side says, “This is all normal science,” and the other says, “This is civilization roulette,” many readers reasonably conclude that someone is spinning. Without clear explanation, they are not irrational for feeling suspicious. They are reacting to a communication vacuum.

Journalists and editors face their own version of the problem. The simplest framing gets attention, but the simplest framing is often the least accurate. “Risky pathogen oversight categories evolve under revised U.S. governance framework” is not exactly a click magnet. “Scientists made something scarier” is easier to sell, but it can erase key distinctions that the public actually needs in order to judge risk intelligently.

Even policymakers experience the confusion. A senator may genuinely want tighter safeguards and still end up speaking in language so broad that it sweeps routine research into the same bucket as the narrow set of studies that prompted concern in the first place. Meanwhile, institutions that want more public trust sometimes default to technical language so dense it sounds like it was written by a committee trapped in a spreadsheet. This is how everyone ends up annoyed, suspicious, and no better informed.

That is why misunderstanding gain-of-function research is not just a semantic issue. It affects careers, oversight, public trust, and preparedness. People make decisions based on the words available to them. If the words are muddy, the decisions get muddy too. And in a field where the stakes include both scientific progress and public safety, muddy is not good enough.

Conclusion

Gain-of-function research is misunderstood because the term is too broad for the way it is commonly used and too politically loaded for the way it is commonly heard. Some of this work is routine and essential. Some of it deserves strict scrutiny. A very small subset may be too risky to justify. Those positions can all be true at the same time.

The real challenge is not choosing between scientific freedom and public safety as if they are opposing teams in matching jerseys. The challenge is building a conversation and an oversight system precise enough to protect both. That means better definitions, better transparency, better risk review, and better public communication. If society cannot tell the difference between basic biological inquiry and the narrow category of experiments that truly raise exceptional concern, then the debate will keep rewarding heat over light.

And when the topic is pathogen research, “more heat, less light” is not exactly the vibe we should be aiming for.